Barinthus Biotherapeutics plc (BRNS)
Barinthus Biotherapeutics plc operates in the Biotechnology industry of the Healthcare sector, headquartered in Germantown, MD, US. The stock last traded at $0.74, down 2.49% on the session, giving a market capitalisation of $30.2M. On trailing twelve-month figures it carries a trailing P/E of -0.72, a net margin of 0.0%. Its beta of -0.36 implies it has historically moved less than the broad market.
Barinthus Biotherapeutics PLC is a clinical-stage biopharmaceutical company focused on developing novel immunotherapeutic drug candidates for treating autoimmune and inflammatory diseases. The company is prioritizing the development of its proprietary SNAP-TI platform, designed to promote immune tolerance, with its lead candidate VTP-1000 targeting celiac disease. It is also developing VTP-300 for chronic hepatitis B using viral vector platform technologies, aimed at inducing disease-specific immune responses.
Barinthus Biotherapeutics plc is most often compared with the following Healthcare names: